Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVFMNASDAQ:EVLONASDAQ:GLMDNASDAQ:REVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVFMEvofem Biosciences$0.01-4.3%$0.01$0.01▼$0.02$1.02M-0.74588,279 shs11,706 shsEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.06$9K0.8414,841 shs25 shsGLMDGalmed Pharmaceuticals$1.41-6.0%$2.29$1.33▼$23.80$908K0.7894,172 shs18,573 shsREVBRevelation Biosciences$2.59-2.8%$3.63$2.36▼$60.80$2.35M0.17113,010 shs16,407 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVFMEvofem Biosciences-4.26%-4.26%+8.43%-6.25%-57.14%EVLOEvelo Biosciences0.00%0.00%-80.00%0.00%-99.00%GLMDGalmed Pharmaceuticals+5.63%-13.79%-22.68%-54.82%-61.48%REVBRevelation Biosciences+2.69%-5.65%-23.50%-74.60%-93.56%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVFMEvofem Biosciences0.2308 of 5 stars0.00.00.04.80.00.00.0EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AGLMDGalmed Pharmaceuticals1.0461 of 5 stars0.03.00.00.02.12.50.6REVBRevelation Biosciences1.4669 of 5 stars0.05.00.00.02.80.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVFMEvofem Biosciences 0.00N/AN/AN/AEVLOEvelo Biosciences 0.00N/AN/AN/AGLMDGalmed Pharmaceuticals 0.00N/AN/AN/AREVBRevelation Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVFMEvofem Biosciences$11.39M0.09N/AN/A($2.64) per share0.00EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/A$33.02 per shareN/AREVBRevelation BiosciencesN/AN/AN/AN/A$402.10 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVFMEvofem Biosciences$52.98M-$0.21N/A∞N/A-46.42%-91.97%-61.93%N/AEVLOEvelo Biosciences-$114.53MN/A0.00∞N/AN/AN/AN/A4/3/2025 (Estimated)GLMDGalmed Pharmaceuticals-$6.91M-$16.66N/A∞N/AN/A-28.75%-24.98%5/28/2025 (Estimated)REVBRevelation Biosciences-$120K-$139.86N/AN/AN/AN/A-193.51%-84.00%5/9/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVFMEvofem BiosciencesN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVFMEvofem BiosciencesN/A0.110.09EVLOEvelo BiosciencesN/AN/AN/AGLMDGalmed PharmaceuticalsN/A7.037.03REVBRevelation BiosciencesN/A1.641.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVFMEvofem Biosciences0.22%EVLOEvelo Biosciences0.31%GLMDGalmed Pharmaceuticals76.14%REVBRevelation Biosciences12.80%Insider OwnershipCompanyInsider OwnershipEVFMEvofem Biosciences0.21%EVLOEvelo Biosciences1.02%GLMDGalmed Pharmaceuticals19.80%REVBRevelation Biosciences0.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVFMEvofem Biosciences120113.36 million113.12 millionNot OptionableEVLOEvelo Biosciences12018.98 million18.79 millionNo DataGLMDGalmed Pharmaceuticals20644,000516,000Not OptionableREVBRevelation Biosciences10905,000268,000Not OptionableREVB, GLMD, EVLO, and EVFM HeadlinesRecent News About These CompaniesRevelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Down 61.9% in MarchMarch 27, 2025 | americanbankingnews.comRevelation Biosciences (REVB) Projected to Post Earnings on FridayMarch 26, 2025 | americanbankingnews.comGemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear CellsMarch 17, 2025 | businesswire.comRevelation Biosciences to Host Fireside Chat at 37th Annual Roth ConferenceMarch 13, 2025 | businesswire.comRevelation Biosciences reports Q4 EPS ($4.98) vs ($133.64) last yearMarch 8, 2025 | markets.businessinsider.comRevelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD PatientsFebruary 26, 2025 | businesswire.comRevelation Biosciences, Inc. Receives Continued NASDAQ Listing ApprovalFebruary 24, 2025 | businesswire.comREVB Start 1B Trial and Announces SplitJanuary 29, 2025 | msn.comRevelation Biosciences Inc trading halted, news pendingJanuary 27, 2025 | markets.businessinsider.comRevelation Biosciences announces 1-for-16 reverse stock splitJanuary 24, 2025 | markets.businessinsider.comRevelation Biosciences stock hits 52-week low at $0.28January 24, 2025 | msn.comRevelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025January 24, 2025 | businesswire.comRevelation Biosciences starts Phase 1b clinical study of Gemini in CKDJanuary 22, 2025 | markets.businessinsider.comRevelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD PatientsJanuary 21, 2025 | businesswire.comRevelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025January 13, 2025 | businesswire.comRevelation Biosciences Inc (REVB) Stock Settles at $0.65: What’s Contributing to This Price Point?January 6, 2025 | bovnews.comNasdaq Grants Revelation Biosciences Inc. Continued ListingJanuary 6, 2025 | finance.yahoo.comRevelation Biosciences (REVB) Receives a Buy from Roth MKMDecember 8, 2024 | markets.businessinsider.comRevelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross ProceedsDecember 3, 2024 | businesswire.comREVB Gets FDA Go AheadDecember 2, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREVB, GLMD, EVLO, and EVFM Company DescriptionsEvofem Biosciences NASDAQ:EVFM$0.0090 0.00 (-4.26%) As of 09:30 AM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Evelo Biosciences NASDAQ:EVLO$0.0005 0.00 (0.00%) As of 04/1/2025Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Galmed Pharmaceuticals NASDAQ:GLMD$1.41 -0.09 (-6.00%) As of 10:24 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Revelation Biosciences NASDAQ:REVB$2.59 -0.08 (-2.85%) As of 10:22 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Reasons Why Halliburton is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
